[A Case of Long-Term Survival Achieved by Chemotherapy for Multiple Metastases Occurring 22 Years after Surgery for Rectal Cancer].
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
추출되지 않음
I · Intervention 중재 / 시술
second-line FOLFOX plus bevacizumab(Bmab)and third-line FTD/TPI plus Bmab
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The recurrence of colorectal cancer 22 years post-surgery was the longest reported case in Japan. This case demonstrates that long-term survival can be achieved even in unresectable late-onset recurrent rectal cancer through persistent and multidisciplinary chemotherapy.
Late recurrence of colorectal cancer, especially more than 5 years after curative resection, is rare, accounting for less than 0.5% of all cases.
APA
Morimoto A, Tochigi T, et al. (2025). [A Case of Long-Term Survival Achieved by Chemotherapy for Multiple Metastases Occurring 22 Years after Surgery for Rectal Cancer].. Gan to kagaku ryoho. Cancer & chemotherapy, 52(13), 1324-1326.
MLA
Morimoto A, et al.. "[A Case of Long-Term Survival Achieved by Chemotherapy for Multiple Metastases Occurring 22 Years after Surgery for Rectal Cancer].." Gan to kagaku ryoho. Cancer & chemotherapy, vol. 52, no. 13, 2025, pp. 1324-1326.
PMID
41546336 ↗
Abstract 한글 요약
Late recurrence of colorectal cancer, especially more than 5 years after curative resection, is rare, accounting for less than 0.5% of all cases. We report a valuable case of a 72-year-old female who was diagnosed multiple metastases 22 years after undergoing surgery for rectal cancer in her 50s. Initial examination revealed elevated CEA and various metastatic lesions including a right iliopsoas muscle tumor, multiple pulmonary nodules, and widespread multiple lymphadenopathy. Biopsy of the iliopsoas mass confirmed adenocarcinoma, consistent with her previous rectal cancer. Systemic chemotherapy was initiated, starting with FOLFIRI plus panitumumab(Pmab), which achieved a partial response. Due to skin toxicity from Pmab, it was switched to cetuximab(Cmab), and FOLFIRI was continued for 71 courses. Subsequently, the patient experienced disease progression and received second-line FOLFOX plus bevacizumab(Bmab)and third-line FTD/TPI plus Bmab. Furthermore, FOLFIRI plus Pmab was rechallenged. Ultimately, the patient died of the original disease 6 years and 1 month after the initiation of chemotherapy, and 28 years after the initial surgery. The recurrence of colorectal cancer 22 years post-surgery was the longest reported case in Japan. This case demonstrates that long-term survival can be achieved even in unresectable late-onset recurrent rectal cancer through persistent and multidisciplinary chemotherapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.